Analyzing the Price-to-Earnings Ratio of Tiziana Life Sciences Ltd (TLSA) – News Heater (2024)

• Melissa Arnold
• June 25, 2024
• Trending

The 36-month beta value for TLSA is also noteworthy at 0.64. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for TLSA is 121.18M, and at present, short sellers hold a 0.15% of that float. The average trading volume of TLSA on June 25, 2024 was 242.35K shares.

TLSA) stock’s latest price update

The stock of Tiziana Life Sciences Ltd (NASDAQ: TLSA) has increased by 18.50 when compared to last closing price of 0.80.Despite this, the company has seen a gain of 28.11% in its stock price over the last five trading days. proactiveinvestors.com reported 2024-06-11 that Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab, a fully human anti-CD3 monoclonal antibody, has demonstrated the ability to induce T regulatory cell production when administered intranasally.

TLSA’s Market Performance

Tiziana Life Sciences Ltd (TLSA) has experienced a 28.11% rise in stock performance for the past week, with a 17.04% rise in the past month, and a 103.87% rise in the past quarter. The volatility ratio for the week is 12.36%, and the volatility levels for the past 30 days are at 12.09% for TLSA. The simple moving average for the past 20 days is 6.95% for TLSA’s stock, with a 50.92% simple moving average for the past 200 days.

Analysts’ Opinion of TLSA

Many brokerage firms have already submitted their reports for TLSA stocks, with B. Riley Securities repeating the rating for TLSA by listing it as a “Buy.” The predicted price for TLSA in the upcoming period, according to B. Riley Securities is $8 based on the research report published on December 22, 2020 of the previous year 2020.

TLSA Trading at 25.42% from the 50-Day Moving Average

After a stumble in the market that brought TLSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.71% of loss for the given period.

Volatility was left at 12.09%, however, over the last 30 days, the volatility rate increased by 12.36%, as shares surge +27.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +108.49% upper at present.

During the last 5 trading sessions, TLSA rose by +28.11%, which changed the moving average for the period of 200-days by +24.90% in comparison to the 20-day moving average, which settled at $0.8967. In addition, Tiziana Life Sciences Ltd saw 69.29% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for TLSA

The total capital return value is set at -1.78.

Based on Tiziana Life Sciences Ltd (TLSA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -31.18. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -1434.29.

Currently, EBITDA for the company is -15.34 million with net debt to EBITDA at 0.09.

Conclusion

In summary, Tiziana Life Sciences Ltd (TLSA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

• Tags:NASDAQ:TLSA, Tiziana Life Sciences Ltd, TLSA, TLSA stock